COPD
MCID: PLM129
MIFTS: 74

Pulmonary Disease, Chronic Obstructive (COPD)

Categories: Respiratory diseases

Aliases & Classifications for Pulmonary Disease, Chronic Obstructive

MalaCards integrated aliases for Pulmonary Disease, Chronic Obstructive:

Name: Pulmonary Disease, Chronic Obstructive 57 75 74 44 38
Chronic Obstructive Pulmonary Disease 12 75 37 29 6 3 15 63 17
Copd 57 12 74 43 3 63
Chronic Obstructive Lung Disease 12 74 15
Pulmonary Disease, Chronic Obstructive, Severe Early-Onset 57 13
Pulmonary Disease, Chronic Obstructive, Susceptibility to 29 6
Chronic Obstructive Airway Disease 12 72
Pulmonary Disease, Obstructive, Chronic, Susceptibility to 40
Severe Early-Onset Chronic Obstructive Pulmonary Disease 74
Chronic Obstructive Pulmonary Disease of Horses 72
Pulmonary Disease Chronic Obstructive 55
Upper Respiratory Infections 72
Common Cold 72
Cold 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3083
OMIM 57 606963
KEGG 37 H01714
MeSH 44 D029424
NCIt 50 C3199
SNOMED-CT 68 13645005
UMLS 72 C0009443 C0024117 C0041912 more

Summaries for Pulmonary Disease, Chronic Obstructive

KEGG : 37
Chronic obstructive pulmonary disease (COPD) is a representative chronic inflammatory disorder of the lungs that includes chronic bronchitis and emphysema. COPD is characterized by airway inflammation and progressive airflow obstruction, most commonly caused by cigarette smoking. The major symptoms of which patients complain are cough, breathlessness, and sputum production. COPD is associated with underlying inflammation in response to chronic exposure to noxious particulates and gases and with a number of comorbid conditions. The onset of COPD generally occurs in the 6th to 8th decades of life. Early onset COPD is defined as disease onset before the age of 50 years, irrespective of smoking history. The presence of persons with early onset, severely reduced pulmonary function suggests that individuals may vary in their genetic susceptibility to the effects of smoking. Alpha-1-antitrypsin deficiency is the only proven genetic risk factor for COPD. Bronchodilators are the mainstay of treatment since they improve lung function and reduce acute exacerbations. Long-acting inhaled bronchodilators are recommended as first line treatment for patients with persistent symptoms.

MalaCards based summary : Pulmonary Disease, Chronic Obstructive, also known as chronic obstructive pulmonary disease, is related to meningitis and bronchitis, and has symptoms including tremor, fever and angina pectoris. An important gene associated with Pulmonary Disease, Chronic Obstructive is SERPINA1 (Serpin Family A Member 1), and among its related pathways/superpathways are Interleukin-4 and 13 signaling and Rheumatoid arthritis. The drugs mometasone furoate and Caspofungin have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotype is chronic obstructive pulmonary disease.

OMIM : 57 Chronic obstructive pulmonary disease (COPD) is a common, complex disorder associated with substantial morbidity and mortality. COPD is defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) (Silverman et al., 2002; Celedon et al., 2004). (606963)

MedlinePlus : 43 COPD (chronic obstructive pulmonary disease) makes it hard for you to breathe. The two main types are chronic bronchitis and emphysema. The main cause of COPD is long-term exposure to substances that irritate and damage the lungs. This is usually cigarette smoke. Air pollution, chemical fumes, or dust can also cause it. At first, COPD may cause no symptoms or only mild symptoms. As the disease gets worse, symptoms usually become more severe. They include A cough that produces a lot of mucus Shortness of breath, especially with physical activity Wheezing Chest tightness Doctors use lung function tests, imaging tests, and blood tests to diagnose COPD. There is no cure. Treatments may relieve symptoms. They include medicines, oxygen therapy, surgery, or a lung transplant. Quitting smoking is the most important step you can take to treat COPD. NIH: National Heart, Lung, and Blood Institute

CDC : 3 Chronic obstructive pulmonary disease, or COPD, refers to a group of diseases that cause airflow blockage and breathing-related problems. It includes emphysema and chronic bronchitis.

UniProtKB/Swiss-Prot : 74 Pulmonary disease, chronic obstructive: A common, complex disorder defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC).

PubMed Health : 63 About chronic obstructive pulmonary disease: COPD, or chronic obstructive pulmonary (PULL-mun-ary) disease, is a progressive disease that makes it hard to breathe. "Progressive" means the disease gets worse over time. COPD can cause coughing that produces large amounts of mucus (a slimy substance), wheezing, shortness of breath, chest tightness, and other symptoms. Cigarette smoking is the leading cause of COPD. Most people who have COPD smoke or used to smoke. Long-term exposure to other lung irritants—such as air pollution, chemical fumes, or dust—also may contribute to COPD.

Wikipedia : 75 Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by... more...

Related Diseases for Pulmonary Disease, Chronic Obstructive

Diseases related to Pulmonary Disease, Chronic Obstructive via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1753)
# Related Disease Score Top Affiliating Genes
1 meningitis 33.3 TNF CXCL8 CRP
2 bronchitis 32.2 TNF SERPINA1 ELANE CXCL8 CRP
3 lung disease 32.0 TNF SERPINA1 PDE4A HMOX1 ELANE CXCL8
4 chlamydia 31.7 TNF CXCL8 CRP
5 respiratory failure 31.7 TNF SERPINA1 PDE4A ELANE CXCL8 CRP
6 pulmonary emphysema 31.7 SERPINA1 MMP12 MMP1 HMOX1 ELANE
7 pneumonia 31.6 TNF ELANE CXCL8 CRP
8 pulmonary edema 31.6 TNF HMOX1 CXCL8 CRP
9 atherosclerosis susceptibility 31.5 TUG1 TNF CRP
10 alpha-1-antitrypsin deficiency 31.5 SERPINA3 SERPINA1 ELANE CXCL8
11 acute respiratory distress syndrome 31.5 TNF ELANE CXCL8
12 bronchiectasis 31.5 SERPINA3 SERPINA1 ELANE CXCL8
13 bronchial disease 31.4 TNF PDE4A ELANE CXCL8
14 bronchiolitis 31.3 TNF CXCL8 CRP
15 myeloma, multiple 31.3 TUG1 TNF MEG3 CXCL8 CRP
16 carotid stenosis 31.3 TNF MMP1 CRP
17 periodontitis 31.3 TNF MMP1 CXCL8 CRP
18 sleep apnea 31.2 TNF CXCL8 CRP
19 pulpitis 31.2 TNF MMP1 CXCL8
20 liver disease 31.2 TNF SERPINA3 SERPINA1 MEG3
21 endocarditis 31.1 TNF CXCL8 CRP
22 pneumoconiosis 31.1 TNF SERPINA1 CXCL8
23 bacterial pneumonia 31.1 ELANE CXCL8 CRP
24 pyelonephritis 31.1 TNF CXCL8 CRP
25 brucellosis 31.1 TNF CXCL8 CRP
26 vascular disease 31.1 TNF HMOX1 ELANE CRP
27 peritonitis 31.1 TNF CXCL8 CRP
28 gastrointestinal system disease 31.1 TNF SERPINA1 CXCL8 CRP
29 adult respiratory distress syndrome 31.1 TNF ELANE CXCL8
30 bacterial infectious disease 31.0 TNF ELANE CXCL8 CRP
31 synovitis 31.0 TNF MMP1 CXCL8 CRP
32 gastroenteritis 31.0 TNF CXCL8 CRP
33 perinatal necrotizing enterocolitis 31.0 TNF CXCL8 CRP
34 preterm premature rupture of the membranes 31.0 MMP1 CXCL8 CRP
35 pleurisy 31.0 TNF CXCL8 CRP
36 proteasome-associated autoinflammatory syndrome 1 31.0 TNF PDE4A ELANE CXCL8 CRP
37 cystitis 31.0 TNF CXCL8 CRP
38 pulmonary fibrosis, idiopathic 31.0 TNF MMP1 ELANE CXCL8
39 respiratory system disease 30.9 TNF SERPINA1 PDE4A ELANE CXCL8 CRP
40 severe acute respiratory syndrome 30.8 TNF CXCL8 CRP
41 bone inflammation disease 30.8 TNF MMP1 CXCL8 CRP
42 vasculitis 30.8 TNF SERPINA1 ELANE CRP
43 temporal arteritis 30.8 TNF SERPINA3 CRP
44 bacterial sepsis 30.8 TNF ELANE CXCL8 CRP
45 obstructive jaundice 30.8 TNF CXCL8 CRP
46 pyuria 30.8 CXCL8 CRP
47 bladder cancer 30.8 TUG1 TNF TINCR SNHG5 MEG3
48 acute pancreatitis 30.8 ELANE CXCL8 CRP
49 intestinal disease 30.7 TNF CXCL8 CRP
50 leptospirosis 30.6 TNF CXCL8 CRP

Comorbidity relations with Pulmonary Disease, Chronic Obstructive via Phenotypic Disease Network (PDN):


Bronchitis Heart Disease

Graphical network of the top 20 diseases related to Pulmonary Disease, Chronic Obstructive:



Diseases related to Pulmonary Disease, Chronic Obstructive

Symptoms & Phenotypes for Pulmonary Disease, Chronic Obstructive

Human phenotypes related to Pulmonary Disease, Chronic Obstructive:

32
# Description HPO Frequency HPO Source Accession
1 chronic obstructive pulmonary disease 32 HP:0006510

Clinical features from OMIM:

606963

UMLS symptoms related to Pulmonary Disease, Chronic Obstructive:


tremor, fever, angina pectoris, pruritus, tinnitus, snoring, rhinorrhea, sore throat, coughing, vertigo/dizziness, equilibration disorder, catarrh, upper respiratory tract inflammation

Drugs & Therapeutics for Pulmonary Disease, Chronic Obstructive

PubMed Health treatment related to Pulmonary Disease, Chronic Obstructive: 63

COPD has no cure yet. However, lifestyle changes and treatments can help you feel better, stay more active, and slow the progress of the disease. The goals of COPD treatment include: Relieving your symptomsSlowing the progress of the diseaseImproving your exercise tolerance (your ability to stay active)Preventing and treating complicationsImproving your overall health To assist with your treatment, your family doctor may advise you to see a pulmonologist. This is a doctor who specializes in treating lung disorders.

Drugs for Pulmonary Disease, Chronic Obstructive (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1089)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
2
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
3
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
4
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
5
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
6
Docosanol Approved, Investigational Phase 4 30303-65-2, 661-19-8 12620
7
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
Azithromycin Approved Phase 4 83905-01-5 447043 55185
11
Fenoterol Approved, Investigational Phase 4 13392-18-2 3343
12
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
13
Norflurane Approved, Experimental Phase 4 811-97-2
14
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
15
Bosentan Approved, Investigational Phase 4 147536-97-8 104865
16
Terbutaline Approved Phase 4 23031-25-6 5403
17
Fosinopril Approved Phase 4 98048-97-6 55891
18
Bisoprolol Approved Phase 4 66722-44-9 2405
19
Sertraline Approved Phase 4 79617-96-2 68617
20
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
21
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
22
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
23
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
24
Riociguat Approved Phase 4 625115-55-1
25
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
26
Ledipasvir Approved Phase 4 1256388-51-8 67505836
27
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
28
Desflurane Approved Phase 4 57041-67-5 42113
29
Remifentanil Approved Phase 4 132875-61-7 60815
30
Montelukast Approved Phase 4 158966-92-8 5281040
31
Ticagrelor Approved Phase 4 274693-27-5 9871419
32
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
33
Dobutamine Approved Phase 4 34368-04-2 36811
34
Chlorpheniramine Approved Phase 4 132-22-9, 113-92-8 2725
35
Phenoxyethanol Approved Phase 4 122-99-6 31236
36
Ribavirin Approved Phase 4 36791-04-5 37542
37
Mycophenolic acid Approved Phase 4 24280-93-1 446541
38
Ibuprofen Approved Phase 4 15687-27-1 3672
39
Iodine Approved, Investigational Phase 4 7553-56-2 807
40
Povidone Approved Phase 4 9003-39-8
41
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
42
Sucralfate Approved Phase 4 54182-58-0
43
Ondansetron Approved Phase 4 99614-02-5 4595
44
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
45
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
46
Ergotamine Approved Phase 4 113-15-5 8223
47
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
48
Nortriptyline Approved Phase 4 72-69-5 4543
49
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
50
Pantoprazole Approved Phase 4 102625-70-7 4679

Interventional clinical trials:

(show top 50) (show all 6411)
# Name Status NCT ID Phase Drugs
1 Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease: A Prospective, Randomized, Double-Blind Placebo-Controlled Study of Intermittent, Prophylactic Antibiotic Treatment With Azithromycin Unknown status NCT00132860 Phase 4 azithromycin
2 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
3 Pulmonary Effects of the Combination of Metoprolol and Formoterol in COPD Unknown status NCT00288548 Phase 4 Metoprolol
4 An Efficacy Study of Benzalkonium Chloride Solution Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
5 Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
6 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
7 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD:a Multicentre Randomised Controlled Trial Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
8 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
9 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
10 Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial Unknown status NCT02579200 Phase 4
11 Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD. Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
12 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
13 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
14 Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Ipratropium/Albuterolin Chinese Patients With Moderate-to-severe COPD. Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
15 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD:a Randomised Controlled Trial Unknown status NCT02197871 Phase 4
16 Adherence to Therapy in COPD Patients Under Dose Escalation of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
17 The Lung Attack Alert Study Unknown status NCT01107613 Phase 4
18 Inspiratory Capacity and HRCT Comparison of Nebulized Arformoterol (Brovana) vs. Dry-powder Inhaler Salmeterol (Serevent) Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
19 Exacerbation's Prevention in Patients With COPD in GOLD IV Stage (Very Severe) With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
20 The Treatment Effect of Inhaled Corticosteroid and Long-acting beta2 Agonist Combination Versus Long-acting Anti-cholinergic Agent on Stratified COPD Patients Based on the Levels of Exhaled Nitric Oxide Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
21 The Effects of Simvastatin in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
22 Description of the Ability to Learn How to Handle Inhaler Devices in COPD Unknown status NCT02813200 Phase 4 Seretide® Diskus® 500/550 μg;Ultibro® Breezhaler® 110/50 μg;Spiriva® Respimat® 2,5 μg
23 Evaluation and Treatment of Small Airways in COPD Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
24 Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
25 Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF) Unknown status NCT00668408 Phase 4
26 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Unknown status NCT01116063 Phase 4 Inhaled iloprost
27 Pulmonary Gas Exchange Response to Indacaterol in Stable Symptomatic Chronic Obstructive Pulmonary Disease Patients Unknown status NCT02547558 Phase 4 Indacaterol
28 A Multi-Center, Prospective, Clinical Trial Designed to Study the Efficacy of One-Way Valve Implantation Based on a New Treatment Algorithm in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
29 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics? Unknown status NCT02171338 Phase 4
30 Advair - CRP Study Unknown status NCT00120978 Phase 4 Advair;Flovent
31 Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study. Unknown status NCT00331656 Phase 4
32 Utility of the AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Assessed by the Chartis System Unknown status NCT01460108 Phase 4
33 Randomized,Double-blind, Placebo Controlled Clinical Trial to Evaluate the Efficacy of the Phytotherapic Compound "Bromelin" on Acute Irritative Cough Unknown status NCT01356693 Phase 4 Bromelin;Placebo
34 Targeting of the Small Airways in Patients With COPD: Airway Effects of Tiotropium - Respimat vs Handihaler Unknown status NCT02683668 Phase 4
35 Double-blind, Randomized, Placebo-controlled Clinical Study Investigating Efficacy and Safety of Arbidol (Umifenovir) in Treatment and Prophylaxis of Influenza and Common Cold. Unknown status NCT01651663 Phase 4 Arbidol (Umifenovir);Arbidol (Umifenovir)
36 Reassessment Study of The Effect of N-Acetylcystein on Quality of Life and Air Trapping During Rest and After Exercise Unknown status NCT00476736 Phase 4 Effect on small airways (N-Acetylcystein)
37 The Evaluation of Singulair for the Treatment of Non-Allergic Rhinitis Eosinophil Syndrome (NARES) Unknown status NCT00406094 Phase 4 montelukast;placebo
38 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
39 Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis Unknown status NCT02288156 Phase 4 Capsaicin;placebo
40 Phase 4, Single Centre, Single Blinded,Prospective Randomised Cross Over Comparison on the Physiological Response of Post Extubation Intensive Care Patients to Non-invasive Ventilation Using Either Air O2 or Heliox21 Unknown status NCT01498432 Phase 4 Heliox21;Air O2
41 Clinical Relevance of Middle Meatal Bacteriology During Acute Respiratory Infection in Children - Randomised, Double-Blinded Clinical Study Unknown status NCT00545961 Phase 4 placebo;amoxicillin clavulanate acid
42 A Double Blind Randomised Placebo Controlled Trial of Montelukast in the Treatment of Acute Persistent Cough in Young People and Adults in Primary Care Unknown status NCT01279668 Phase 4 Montelukast;Placebo
43 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Chronic Obstructive Pulmonary Disease Phenotype Unknown status NCT01431625 Phase 4
44 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
45 Ultrasound-guided Transverses Abdominis Plane Block in Inguinal Herniorrhaphy: Randomized Controlled Clinical Trial Unknown status NCT02299908 Phase 4 TAP block with Bupivacaine at 0.25%;Placebo saline solution
46 Liberal Versus Restrictive Transfusion Management in Patients Being Weaned From Prolonged Mechanical Ventilation Unknown status NCT01256645 Phase 4
47 Evaluation Whether Higher Retention Rate is in Those of Combined Methadone With N-Acetyl-Cysteine Compared to Those With Methadone Alone During a Six-month Study Unknown status NCT01047956 Phase 4 Methadone; NAC;Methadone
48 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
49 Cold vs. Laser Internal Urethrotomy Treatment of Urethral Strictures Unknown status NCT01196572 Phase 4
50 Prophylactic Administration of Antibiotics Before Radiofrequency Ablation for Hepatocellular Carcinoma: A Randomized Trial Unknown status NCT02534961 Phase 4 Cefazolin

Search NIH Clinical Center for Pulmonary Disease, Chronic Obstructive

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Aclidinium
Arformoterol
Ascorbic Acid
Ascorbic Acid Powder
Beclomethasone dipropionate
Budesonide
Doxycycline
Echinacea Preparation
Erythromycin
Fluticasone furoate
Fluticasone propionate
Formoterol
Glycopyrronium
Guaifenesin
indacaterol
Indacaterol
Ipratropium
Minocycline
olodaterol
Olodaterol
Olodaterol hydrochloride
Phenylpropanolamine
Phenylpropanolamine Hydrochloride
Pseudoephedrine
Pseudoephedrine Hydrochloride
Pseudoephedrine sulfate
Revefenacin
Roflumilast
Salmeterol
Sodium Ascorbate
Tiotropium
Umeclidinium
Vilanterol
Zinc Acetate
zinc chloride
Zinc Gluconate
Zinc Sulfate
ZINC SULFATE PWDR

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: pulmonary disease, chronic obstructive

Genetic Tests for Pulmonary Disease, Chronic Obstructive

Genetic tests related to Pulmonary Disease, Chronic Obstructive:

# Genetic test Affiliating Genes
1 Chronic Obstructive Pulmonary Disease 29 HMOX1 MMP1 SERPINA1
2 Pulmonary Disease, Chronic Obstructive, Susceptibility to 29

Anatomical Context for Pulmonary Disease, Chronic Obstructive

MalaCards organs/tissues related to Pulmonary Disease, Chronic Obstructive:

41
Lung, Testes, Heart, Liver, Neutrophil, Kidney, Endothelial

Publications for Pulmonary Disease, Chronic Obstructive

Articles related to Pulmonary Disease, Chronic Obstructive:

(show top 50) (show all 30182)
# Title Authors PMID Year
1
Heme oxygenase 1 variations and lung function decline in smokers: proof of replication. 8 71
18519631 2008
2
Association of lung function decline with the heme oxygenase-1 gene promoter microsatellite polymorphism in a general population sample. Results from the European Community Respiratory Health Survey (ECRHS), France. 8 71
16882737 2006
3
The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. 8 71
11875051 2002
4
Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. 8 71
10631150 2000
5
The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). 9 38 8
15175276 2004
6
Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. 9 38 8
14530202 2003
7
Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP. 38 8
22140090 2012
8
FOXO3 deficiency leads to increased susceptibility to cigarette smoke-induced inflammation, airspace enlargement, and chronic obstructive pulmonary disease. 38 8
21690325 2011
9
Variants in FAM13A are associated with chronic obstructive pulmonary disease. 38 8
20173748 2010
10
The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. 38 8
19933216 2010
11
Association of TRPV4 gene polymorphisms with chronic obstructive pulmonary disease. 38 8
19279160 2009
12
Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. 38 8
18488036 2008
13
Antielastin autoimmunity in tobacco smoking-induced emphysema. 38 8
17450149 2007
14
The SERPINE2 gene and chronic obstructive pulmonary disease. 38 8
16773582 2006
15
The SERPINE2 gene is associated with chronic obstructive pulmonary disease. 38 8
16358219 2006
16
Cryptic haplotypes of SERPINA1 confer susceptibility to chronic obstructive pulmonary disease. 38 8
16278826 2006
17
Genome-wide linkage analysis of bronchodilator responsiveness and post-bronchodilator spirometric phenotypes in chronic obstructive pulmonary disease. 38 8
12719384 2003
18
Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. 38 8
11914989 2002
19
Traditional Chinese exercise (TCE) on pulmonary rehabilitation in patients with stable chronic obstructive pulmonary disease: Protocol for a systematic review and network meta-analysis. 38 17
31277166 2019
20
The Qigong Wuqinxi for chronic obstructive pulmonary disease: Protocol for a systematic review and meta-analysis. 38 17
31348315 2019
21
Hedgehog-interacting protein is a COPD susceptibility gene: the Rotterdam Study. 8
19996190 2010
22
MMP12, lung function, and COPD in high-risk populations. 8
20018959 2009
23
Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. 8
19800047 2009
24
A frequent functional SNP in the MMP1 promoter is associated with higher disease severity in recessive dystrophic epidermolysis bullosa. 71
18030675 2008
25
Matrix metalloproteinase-12 gene expression in human vascular smooth muscle cells. 8
12622720 2003
26
A single nucleotide polymorphism in the matrix metalloproteinase-1 (MMP-1) promoter influences amnion cell MMP-1 expression and risk for preterm premature rupture of the fetal membranes. 71
11741975 2002
27
Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. 8
10807873 2000
28
A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. 71
9850057 1998
29
C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. 17
31291514 2019
30
MCP1 -2518 polymorphism and chronic obstructive pulmonary disease in Taiwanese men. 9 38
20497022 2010
31
Improving diagnosis and management of alpha-1 antitrypsin deficiency in primary care: translating knowledge into action. 9 38
20486818 2010
32
[Role of glucocorticoid receptor and nuclear factor-kappaB in patients with stable chronic obstructive pulmonary disease]. 9 38
20450542 2010
33
Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. 9 38
20397815 2010
34
Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. 9 38
20100935 2010
35
Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. 9 38
19643942 2010
36
Peripheral neuropathy in chronic obstructive pulmonary disease. 9 38
20214459 2010
37
A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. 9 38
19880675 2010
38
Genetic polymorphisms of the serotonin transporter, but not the 2a receptor or nitric oxide synthetase, are associated with pulmonary hypertension in chronic obstructive pulmonary disease. 9 38
19556740 2010
39
Interleukin-13: prospects for new treatments. 9 38
19878194 2010
40
Alpha1-antitrypsin deficiency: forgotten etiology. 9 38
20090075 2010
41
Development of novel microarray methodology for the study of mutations in the SERPINA1 and ADRB2 genes--their association with Obstructive Pulmonary Disease and Disseminated Bronchiectasis in Greek patients. 9 38
19747908 2010
42
The role of the phosphodiesterase-4 inhibitor, roflumilast, in chronic obstructive pulmonary disease. 9 38
20150838 2010
43
Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. 9 38
20008877 2009
44
Il13 promoter (-1055) polymorphisms associated with chronic obstructive pulmonary disease in Taiwanese. 9 38
19995275 2009
45
[The changes and significance of interleukin-16 and CXC chemokine receptor 3 expression in pulmonary artery of smokers with chronic obstructive pulmonary disease]. 9 38
20079227 2009
46
Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors. 9 38
19775099 2009
47
Protease-activated receptors and prostaglandins in inflammatory lung disease. 9 38
19845685 2009
48
A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. 9 38
19376817 2009
49
Genetic polymorphism of GSTT1 and GSTM1 and susceptibility to chronic obstructive pulmonary disease (COPD). 9 38
19664521 2009
50
Real time PCR detection of the PI*Z and PI*S mutations associated with alpha-1 antitrypsin deficiency. 9 38
19956452 2009

Variations for Pulmonary Disease, Chronic Obstructive

ClinVar genetic disease variations for Pulmonary Disease, Chronic Obstructive:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 SERPINA1 NM_001127701.1(SERPINA1): c.1096G> A (p.Glu366Lys) single nucleotide variant Pathogenic rs28929474 14:94844947-94844947 14:94378610-94378610
2 SERPINA1 NM_001127701.1(SERPINA1): c.863A> T (p.Glu288Val) single nucleotide variant Pathogenic rs17580 14:94847262-94847262 14:94380925-94380925
3 SERPINA1 NM_001127701.1(SERPINA1): c.194T> C (p.Leu65Pro) single nucleotide variant Pathogenic/Likely pathogenic rs28931569 14:94849381-94849381 14:94383044-94383044
4 HMOX1 HMOX1, (GT)n REPEAT undetermined variant risk factor

Copy number variations for Pulmonary Disease, Chronic Obstructive from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 230707 8 1 12700000 Copy number DEFB4 Chronic obstructive pulmonary disease

Expression for Pulmonary Disease, Chronic Obstructive

Search GEO for disease gene expression data for Pulmonary Disease, Chronic Obstructive.

Pathways for Pulmonary Disease, Chronic Obstructive

GO Terms for Pulmonary Disease, Chronic Obstructive

Cellular components related to Pulmonary Disease, Chronic Obstructive according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 TNF SERPINA3 SERPINA1 MMP12 HMOX1 ELANE

Biological processes related to Pulmonary Disease, Chronic Obstructive according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.73 TNF MMP1 HMOX1 CXCL8
2 embryonic digestive tract development GO:0048566 9.46 TNF CXCL8
3 negative regulation of growth of symbiont in host GO:0044130 9.4 TNF ELANE
4 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.37 TNF ELANE
5 extracellular matrix disassembly GO:0022617 9.33 MMP12 MMP1 ELANE
6 negative regulation of lipid storage GO:0010888 9.32 TNF CRP
7 positive regulation of chemokine biosynthetic process GO:0045080 9.26 TNF HMOX1
8 positive regulation of smooth muscle cell proliferation GO:0048661 9.13 TNF HMOX1 ELANE
9 acute-phase response GO:0006953 8.8 SERPINA3 SERPINA1 CRP

Molecular functions related to Pulmonary Disease, Chronic Obstructive according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.13 TNF SERPINA1 ELANE
2 endopeptidase activity GO:0004175 8.8 MMP12 MMP1 ELANE

Sources for Pulmonary Disease, Chronic Obstructive

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....